Kipp Weiskopf, Whitehead Fellow at The Whitehead Institute and Hematology & Oncology Fellow at The Dana-Farber Cancer Institute, shares his insights into key challenges and leading therapies currently targeting the CD47-SIRPa axis.

Click here to download your copy